Animal health companies not exempt from FDA marketing regs, either

The FDA is keeping an eye on the marketing claims of animal health drugmakers, just like it does for makers of human drugs. The agency issued Paris-based AB Science a warning letter regarding its Kinavet-CA1 canine drug, intended for mast cell tumors in dogs, for allegedly boasting its off-label uses without approval. It slams the vet med company for not only omitting the drug's harmful effects on humans but brazenly touting it for treating atopic dermatitis in dogs. "This evidence that Kinavet is an unapproved new animal drug is particularly compelling," the warning letter reads. More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.